Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $184M | $-50M | $-84M | $-111M | -37.0% | 138.8% | -52.2% |
| 2024 | $77M | $-155M | $-175M | $-219M | -62.3% | 32386.9% | -5.2% |
| 2023 | $0M | $-175M | $-184M | $-169M | -74.3% | -60.2% | 29.8% |
| 2022 | $1M | $-134M | $-142M | $-128M | -177.4% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 183.88 |
| Operating Revenue | 223.37 |
| Cost Of Revenue | 4.74 |
| Gross Profit | 179.14 |
| Operating Expense | 230.69 |
| Research And Development | 71.43 |
| Selling General And Administration | 159.26 |
| Total Expenses | 235.43 |
| Operating Income | -51.55 |
| Total Operating Income As Reported | -68.58 |
| EBITDA | -49.64 |
| Normalized EBITDA | -32.61 |
| EBIT | -50.84 |
| Interest Income | 18.12 |
| Interest Expense | 32.66 |
| Net Interest Income | -14.54 |
| Other Non Operating Income Expenses | -0.38 |
| Other Income Expense | -17.41 |
| Interest Income Non Operating | 18.12 |
| Interest Expense Non Operating | 32.66 |
| Net Non Operating Interest Income Expense | -14.54 |
| Pretax Income | -83.50 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | -0.02 |
| Net Income Continuous Operations | -83.50 |
| Net Income From Continuing And Discontinued Operation | -83.50 |
| Net Income From Continuing Operation Net Minority Interest | -83.50 |
| Net Income | -83.50 |
| Net Income Common Stockholders | -83.50 |
| Net Income Including Noncontrolling Interests | -83.50 |
| Normalized Income | -66.49 |
| Diluted NI Availto Com Stockholders | -83.50 |
| Basic Average Shares | 666.66 |
| Diluted Average Shares | 666.66 |
| Reconciled Depreciation | 1.20 |
| Reconciled Cost Of Revenue | 4.74 |
| Total Unusual Items | -17.03 |
| Total Unusual Items Excluding Goodwill | -17.03 |
| Special Income Charges | -17.03 |
| Other Special Charges | - |
| Restructuring And Mergern Acquisition | 17.03 |
| General And Administrative Expense | - |
| Other Gand A | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Geron Corporationthis co. | GERN | $776M | -9.30 | 3.44 | -37.0% | -16.53 |
| Esperion Therapeutics, Inc. | ESPR | $806M | - | - | 7.5% | 13.94 |
| Lumexa Imaging Holdings, Inc. | LMRI | $792M | -16.81 | 1.35 | -8.0% | 11.96 |
| Eton Pharmaceuticals, Inc. | ETON | $792M | -172.06 | 30.27 | -17.6% | 248.97 |
| Phathom Pharmaceuticals, Inc. | PHAT | $786M |
| - |
| - |
| - |
| - |
| - |
| -3.55 |
| -1.79 |
| 50.5% |
| -5.69 |
| Kura Oncology, Inc. | KURA | $779M | - | 4.47 | -160.0% | - |
| BioAge Labs, Inc. | BIOA | $757M | -9.39 | 2.78 | -29.6% | -7.19 |
| EVMN | EVMN | $745M | -10.82 | 3.63 | -33.5% | -8.82 |
| Omeros Corporation | OMER | $742M | -221.45 | -6.12 | 2.8% | -7.97 |
| Peer Median | - | -13.81 | 2.78 | -12.8% | -5.69 | |